Angiomyolipoma pathophysiology: Difference between revisions

Jump to navigation Jump to search
Shivali Marketkar (talk | contribs)
No edit summary
Kalsang Dolma (talk | contribs)
No edit summary
Line 4: Line 4:


Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.


==Pathophysiology==
==Pathophysiology==
Since all three components of an angiomyolipoma (vascular cells, immature smooth muscle cells and fat cells) contain a [[Two-hit hypothesis|"second hit" mutation]], they are believed to have derived from a common [[progenitor cell]] that suffered the common second hit mutation.<ref name=Bissler2010/>
Since all three components of an angiomyolipoma (vascular cells, immature smooth muscle cells and fat cells) contain a [[Two-hit hypothesis|"second hit" mutation]], they are believed to have derived from a common [[progenitor cell]] that suffered the common second hit mutation.


===Microscopic Pathology===
===Microscopic Pathology===
Line 21: Line 20:
[[Image:Renal angiomyolipoma (4) HMB-45 immunostain.JPG|thumb|left|350px|4. Histopathologic image of renal angiomyolipoma. Nephrectomy specimen. The same case as demonstrated in "Image 1". HMB-45 immunostain.]]
[[Image:Renal angiomyolipoma (4) HMB-45 immunostain.JPG|thumb|left|350px|4. Histopathologic image of renal angiomyolipoma. Nephrectomy specimen. The same case as demonstrated in "Image 1". HMB-45 immunostain.]]
<br clear="left"/>
<br clear="left"/>
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Revision as of 17:25, 7 March 2013

Angiomyolipoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Angiomyolipoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Angiomyolipoma pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Angiomyolipoma pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Angiomyolipoma pathophysiology

CDC on Angiomyolipoma pathophysiology

Angiomyolipoma pathophysiology in the news

Blogs on Angiomyolipoma pathophysiology

Directions to Hospitals Treating Angiomyolipoma

Risk calculators and risk factors for Angiomyolipoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Pathophysiology

Since all three components of an angiomyolipoma (vascular cells, immature smooth muscle cells and fat cells) contain a "second hit" mutation, they are believed to have derived from a common progenitor cell that suffered the common second hit mutation.

Microscopic Pathology

1. Histopathologic image of renal angiomyolipoma. Nephrectomy specimen. H & E stain.


2. Histopathologic image of renal angiomyolipoma. Nephrectomy specimen. The same case as demonstrated in "Image 1". H & E stain.


3. Histopathologic image of renal angiomyolipoma. Nephrectomy specimen. The same case as demonstrated in "Image 1". H & E stain.


4. Histopathologic image of renal angiomyolipoma. Nephrectomy specimen. The same case as demonstrated in "Image 1". HMB-45 immunostain.


References

Template:WikiDoc Sources